PROK Stock Forecast: ProKidney Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for ProKidney Corp. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 17 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores ProKidney Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (62): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PROK stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PROK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Citigroup | Maintains | Buy | $10 → $8.00 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 16 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 July 2025 | UBS | Maintains | Buy | — |
| 14 July 2025 | Guggenheim | Maintains | Buy | — |
| 9 July 2025 | Citigroup | Maintains | Buy | — |
| 30 June 2025 | B of A Securities | Downgrade | Underperform | — |
| 30 Sept 2024 | JP Morgan | Initiates | Neutral | — |
| 10 Sept 2024 | Guggenheim | Initiates | Buy | — |
| 4 Sept 2024 | B of A Securities | Maintains | Neutral | — |
| 10 June 2024 | Jefferies | Maintains | Buy | — |
| 29 May 2024 | B of A Securities | Maintains | Neutral | — |
| 7 Mar 2024 | Morgan Stanley | Assumes | Equal-Weight | $3.00 |
| 2 Jan 2024 | B of A Securities | Downgrade | Neutral | — |
| 25 July 2023 | BTIG | Initiates | Buy | — |
| 21 Dec 2022 | Jefferies | Initiates | Buy | — |
| 10 Nov 2022 | Morgan Stanley | Initiates | Equal-Weight | — |
| 18 Oct 2022 | UBS | Initiates | Buy | — |
| 14 Oct 2022 | Citigroup | Initiates | Buy | — |
| 2 Sept 2022 | Evercore ISI Group | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PROK.
This page is one stock. Monday covers all of them.
PROK appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PROK vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, ProKidney Corp. returned −50.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PROK analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 535.8×
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −73.4%
- Return on assets
- −42.9%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ProKidney Corp. has a market value of $415.2M and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $818K. The latest quarter shrank 32.1% year on year.
Net income over the same four quarters: −$165.8M, a −20263.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$159.7M.
ProKidney Corp. employs 231 people — $4K of revenue per employee.
Data provided by Twelve Data
PROK and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PROK’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own ProKidney Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PROK
What is the PROK stock price forecast for 2026-2027?
The median 12-month analyst price target for ProKidney Corp. is $7, with estimates ranging from $1 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PROK stock a buy right now?
Of the 6 analysts covering ProKidney Corp., 4 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ProKidney Corp. 17 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PROK?
As at 21 Nov 2026, ProKidney Corp. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (62 of 100).
Will PROK stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $7, and Ticker Nerd's factor model ranks ProKidney Corp. 17 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PROK stock forecast for 2030?
No analyst covering ProKidney Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PROK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $12 over the next 12 months.
How has PROK stock performed over the past year?
ProKidney Corp. returned -50.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ProKidney Corp. do?
ProKidney Corp. Class A Ordinary Shares represent equity in ProKidney, a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease. The company’s work centers on proprietary autologous cell therapy platforms designed to support kidney function in patients with advanced kidney disease and diabetes.
About ProKidney Corp.
ProKidney Corp. Class A Ordinary Shares represent equity in ProKidney, a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease. The company’s work centers on proprietary autologous cell therapy platforms designed to support kidney function in patients with advanced kidney disease and diabetes. Its lead therapeutic program is directed at treating moderate to severe diabetic kidney disease and other chronic kidney conditions, placing ProKidney in the broader renal therapeutics sector. The company’s current business is concentrated on research, clinical development, and the advancement of its cell therapy candidates, making it a specialized participant in the biotechnology market. ProKidney Corp. is headquartered in Winston-Salem, North Carolina, and its Class A ordinary shares are one of the company’s publicly traded equity classes.
CEO Dr. Bruce Culleton M.D. · 231 employees · United States · https://prokidney.com